IGM Biosciences (IGMS) Projected to Post Earnings on Wednesday

Key Points

• IGM Biosciences is set to announce its Q2 2025 earnings on August 13th, with analysts anticipating earnings of ($0.12) per share and revenue of $0.40 million.
• The company reported a significant earnings surprise in its last quarter, with $1.58 earnings per share against an expectation of ($0.30), alongside revenue of $143.62 million compared to a $3.20 million estimate.
• IGM Biosciences has a market capitalization of $76.95 million and has recently been downgraded from a "hold" to a "sell" rating by Wall Street Zen, with a consensus price target of $5.50.

IGM Biosciences (NASDAQ:IGMS - Get Free Report) is expected to issue its Q2 2025 quarterly earnings data before the market opens on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $0.40 million for the quarter.

IGM Biosciences (NASDAQ:IGMS - Get Free Report) last released its quarterly earnings data on Thursday, July 31st. The company reported $1.58 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $1.88. The company had revenue of $143.62 million during the quarter, compared to analysts' expectations of $3.20 million. IGM Biosciences had a negative net margin of 36.81% and a negative return on equity of 93.35%. On average, analysts expect IGM Biosciences to post $-3 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

IGM Biosciences Stock Performance

NASDAQ IGMS remained flat at $1.27 on Friday. The company's stock had a trading volume of 155,302 shares, compared to its average volume of 464,659. IGM Biosciences has a 1-year low of $0.92 and a 1-year high of $22.50. The stock's 50 day simple moving average is $1.27 and its two-hundred day simple moving average is $1.29. The company has a market cap of $76.35 million, a P/E ratio of -1.41 and a beta of 0.60.

Wall Street Analyst Weigh In

Separately, Wall Street Zen lowered IGM Biosciences from a "hold" rating to a "sell" rating in a research note on Saturday, June 7th. Two analysts have rated the stock with a sell rating and nine have issued a hold rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $5.50.

Hedge Funds Weigh In On IGM Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of IGMS. Invesco Ltd. purchased a new stake in IGM Biosciences during the 1st quarter valued at about $42,000. Acadian Asset Management LLC acquired a new stake in shares of IGM Biosciences during the first quarter worth about $97,000. Finally, AQR Capital Management LLC acquired a new stake in shares of IGM Biosciences during the first quarter worth about $275,000. 42.79% of the stock is owned by hedge funds and other institutional investors.

IGM Biosciences Company Profile

IGM Biosciences, Inc, a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases.